[DISCLOSURE] Celltrion (068270) said on Oct. 14 that it has earned a patent in Australia for its cancer treatment based on Dolastatin 10 derivatives.

The patent focuses mainly on manufacturing method of Dolastatin 10 and the treatments based on the formula.

By Jung Min-kyung ()